Alzchem Group AG raises EBITDA forecast into the range of EUR 80 million for fiscal year 2023 despite slightly lower sales expectation
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014
Trostberg, October 18, 2023 – Alzchem Group AG is significantly raising its earnings forecast for the full year 2023 despite a slightly lower sales expectation. Group EBITDA is expected to grow to approximately EUR 80 million (original forecast: up to EUR 70 million). Group sales are expected to be at or slightly below the previous year’s level of EUR 542.2 million; this is slightly below the most recent forecast.
The higher earnings forecast is based primarily on the very positive development of the high-margin specialty chemicals business. Particularly noteworthy in this respect are the products from the Human Nutrition (Creapure®) and Animal Nutrition (Creamino®) businesses, as well as the guanidine salts (nitroguanidine).
The forecasts for fiscal year 2023 made in the consolidated financial statements as of 31 December 2022 and last specified in July 2023 are therefore adjusted overall as follows:
| 2022 | Original forecast 2023 (according to last specification) | Adjusted forecast 2023 |
Group sales | EUR 542.2 million | Slightly growing | At previous year’s level or slightly below |
Adjusted EBITDA* | EUR 61.4 million | Up to EUR 70 million | Strongly growing to approx. EUR 80 million |
Adjusted | 11.3% | Up to 12% | Noticeably growing |
Inventories | EUR 122.4 million | Stable | Slightly to significantly decreasing |
Inventory intensity (previously inventory ratio) | 22.6% | Stable | Slightly to significantly decreasing |
Equity ratio | 34.5% | Noticeably growing | Significantly growing |
* No adjustments were made. | |||
Contact
Sabine Sieber
Head of Investor Relations & Communications
Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany